In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo
- PMID: 38437698
- DOI: 10.7326/J24-0004
In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo
Abstract
Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916.
Conflict of interest statement
Comment on
-
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757. N Engl J Med. 2023. PMID: 37888916 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials